Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

New five-year data support superiority of Novartis AG's drug Tasigna over Glivec in newly diagnosed Ph+ CML patients


Sunday, 8 Dec 2013 06:00pm EST 

Novartis AG:Says new five-year data support superiority of Novartis drug Tasigna over Glivec in newly diagnosed Ph+ CML patients.Says ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec.Says data demonstrated higher rates of early and deeper molecular response in newly diagnosed patients, including MR4.5, and a reduced risk of progression.Says separate study, ENESTcmr, confirms treatment with Tasigna led to deeper molecular response in patients who switch after long-term treatment with Glivec.Says new data show patients who failed to respond to frontline Glivec achieved higher rates of molecular response with switch to Tasigna versus Glivec dose escalation.